We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Ablation Procedure Effective in Stopping Heavy Menstrual Bleeding

By HospiMedica International staff writers
Posted on 20 Jan 2009
A less invasive procedure for treating heavy menstrual bleeding (amenorrhea), called global endometrial ablation (GEA), preserves the uterus while decreasing menstrual bleeding and shortening patients' recovery time. More...


Researchers at the Mayo Clinic (Rochester, MN, USA) studied the medical records of approximately 816 women who underwent GEA with either a thermal balloon ablation or a radio frequency (RF) ablation device between January 1998 and December 2005; of these, 455 were included in a population-derived cohort (for model development), and 361 were included in a referral-derived cohort (for model validation). Amenorrhea was defined as cessation of bleeding immediately after ablation through at least 12 months following the procedure. Treatment failure was defined as a subsequent hysterectomy or the need for reablation for patients with bleeding or pain. Logistic and Cox proportional hazard regression models were used in model development and validation of potential predictors of outcomes.

The results showed that the amenorrhea rate following GEA was 23%, and the 5-year cumulative failure rate was 16%. Predictors of amenorrhea were age 45 years or older, uterine length less than 9 cm, endometrial thickness less than 4 mm, and use of RF ablation instead of thermal balloon ablation. Predictors of treatment failure included age younger than 45 years, parity of 5 or greater, prior tubal ligation, and history of dysmenorrhea. After global endometrial ablation, 23 women (5.1%) had pelvic pain, three (0.7%) succeeded in becoming pregnant, and none had endometrial cancer. The study was published in the January 2009 issue of Obstetrics and Gynecology.

"We found that only 16% of our subjects required hysterectomy to treat excessive bleeding five years after ablation. That is nearly half of what has generally been reported in the literature to date,” said coauthor gynecologic surgeon Abimbola Famuyide, M.D., of the division of gynecologic surgery. "Optimizing preoperative patient counseling and patient selection could allow failure rates associated with GEA to further decrease.”

During GEA, surgeons use an energy source (heat, cold, and microwave or RF energy) to destroy the uterine lining (endometrium) of the uterus, leaving the other structures intact. Once the cells or the tissue that line the uterus are destroyed, scar tissue forms, and monthly menstrual flow and any accompanying pain typically decrease. The newest forms of GEA were initially thought to be equally effective compared to hysterectomy, with slightly lower complication rates and costs.

Related Links:
Mayo Clinic



Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Absorbable Monofilament Mesh
Phasix Mesh
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.